Biosearch Technologies公司 Biosearch Technologies代理 Biosearch Technologies**代理 Biosearch Technologies中国代理
Biosearch Technologies是专业性荧光定量PCR探针合成及标记服务公司，提供与世界上各种荧光定量PCR仪配套的探标记方式及荧光素。
Biosearch Technologies的根源可以追溯到1978年，现任总裁兼**执行官罗恩 - 库克，博士创立了“Biosearch”，为新兴的生物技术产业提供研究工具。在20世纪80年代，Biosearch自主研发固相DNA合成器，如SAM I, the Cyclone, Biosearch 8700 and Biosearch 8800 Prep。这些生产制造的寡核苷酸的技术，催生新寡核苷酸技术的发展。*引人注目的是1982年，Kary Mullis在Cetus 公司使用了BiosearchSAM I合成DNA创造使用的寡核苷酸，其*终导致的聚合酶链反应（PCR）的发现。
自80年代初以来，Biosearch的**者精炼了寡核苷酸的化学成分核苷酸合成，加速基因组信息的发现和应用。我们的演示补充了我们****的低调修饰选择在荧光探针和引物的设计和制造方面的专业知识。
这些探针是我们的核心焦点，因为它们能够激发生物技术的关键反应和手段：
•药物 基因组研究
•DNA测序
•SNP检测
•基因ex
压力分析我们专有的染料Black HoleQuencher®（BHQ®染料）已经成为荧光淬灭的行业标准，可以设计更有效的荧光探针。当与我们自己充满活力的荧光团合作时，BHQ探针有助于将五个或更多反应复用到单个测定中。
我们广泛的专业修改和标签是Biosearch的优先事项。我们制造我们自己使用的原材料前体，并提供给其他低聚糖制造商，如我们广泛的高品质特种脒化物和支持品系。我们的仪器历史使我们自己的合成和净化机器人得以发展。
我们欢迎有机会与世界各地的**者合作，并推出新的发明基因组学。
生物研究和PCR的发现
Biosearch Technologies的根源可以追溯到1978年，现任总裁兼**执行官Ron Cook博士创建“Biosearch”为新生的生物工业提供研究工具。在20世纪80年代，Biosearch开发和制造了自动化的固相DNA合成仪，如SAM I，Cyclone，Biosearch 8700和Biosearch 8800 Prep。这些仪器制造了oligo核苷酸具有极大的熟练程度，催化了**的发展新罕布什尔sed技术。*着名的是1982年，Caryus公司的Kary Mullis使用Biosearch Sam One DNA合成仪来制备寡核苷酸，用于他的实验，*终导致了聚合酶链反应（PCR）的发现。
Kary Mullis和PCR的发明
Kary Mullis，1973年在加州大学伯克利分校获得生物化学博士学位在1983年春季，将PCR作为扩增人类基因组上特定的感兴趣位点的手段。
之后在他着名的“Philo”驾驶过程中，感染PCR，Kary为数不胜数的工作而努力努力解决实验条件。由于热稳定性聚合酶尚未得到应用，所以必须在每个热循环后添加Klenow，加上发育的滋味。PCR有许多失败和很多原因，因此PCR不应该起作用。毕竟这个想法是如此简单，不应该是以前发明的？不顾许多人的疑虑，并在罗恩·库克（Ron Cook）以及其他支持者的鼓励下，卡里曾经在1983年12月16日进行了**次成功的实验，其余的就是历史！PCR的**授予Cetus公司，该公司是在发现时聘用Kary的公司，后来以3亿美元出售给Hoffmann-La Roche。
PCR的发现永远改变了分子生物学世界。它是用于许多医学和生物应用（如DNA测序和遗传指纹图谱）的标准但不可或缺的研究技术。PCR也是帮助合成寡核苷酸的单一技术核苷酸业务成为一个蓬勃发展的行业。因此，25年后，Biosearch恭维地发展了一种快速回答过去DNA化学问题的技术，正如凯里所说的“丰富和区别”。
PCR的进化
随着PCR引入识别，操纵和扩增DNA的能力，研究可能性蓬勃发展。遗传突变的检测，检测先前未知的遗传物质的存在的能力以及分析退化的DNA的能力都成为常见的做法。例如，使用PCR检测和诊断肌肉营养**和HIV等疾病。
随着科学家们越来越熟悉PCR的技术，他们开始扩展该方法的效用。在20世纪80年代后期，PCR用于测量反应中存在的DNA的量，产生术语“定量PCR”或更简单的q-PCR。该技术通过在90年代初分离Taq聚合酶进一步改进了PCR。热稳定聚合酶可以通过扩增所需的许多循**持活性，并产生更快循环的需求。Russell Higuchi和同事们开发了一个系统同时检测DNA的扩增反应。该系统涉及溴化乙锭，用于用UV光照射样品的热循环仪，以及记录荧光的照相机。
在90年代初期，开发了荧光双标记探针作为实施q-PCR的手段。在公司与荧光探针结合，PCR进一步演变成用于检测任何所需遗传元件的敏感定量工具。因此，测量基因的能力压力和实践基因分型在整个生物技术行业中迅速变得微不足道。现在，随着新型染料和猝灭剂的发展，如来自Biosearch的Black HoleQuencher®，CALFluor®和Quasar®系列染料，PCR的可能性似乎是无止境的。
Since the early 80s, innovators at Biosearch have refined the chemistry of oligonucleotide synthesis to accelerate the discovery and application of genomic information. Our unmatched selecion of oligo modifications is complemented by our demonstrated expertise in the design and manufacture of fluorogenic probes and primers.
Such probes are the core focus for us because they fuel the critical reactions and instruments that power biotechnology:
•Pharmacogenomic research
•DNA Sequencing
•SNP detection
•Gene expression analysis
Our proprietary dyes called the Black Hole Quencher® (BHQ® dyes) have become the industry standard for fluorescence quenching by enabling design of more effective fluorogenic probes. When partnered with our own vibrant fluorophores, BHQ Probes facilitate multiplexing of five or more reactions into a single assay.
Our extensive line of specialty modifications and labels are a priority at Biosearch. We manufacture raw material precursors that we use ourselves and also provide to other oligo manufacturers, such as our extensive line of high quality specialty amidites and supports. Our history with instrumentation has enabled development of our own synthesis and purification robots.
We welcome the opportunity to work with innovators worldwide and enable new inventions that advance the frontier of genomics.
Biosearch and the Discovery of PCR
The roots of Biosearch Technologies can be traced back to 1978 when current President and CEO, Ron Cook, PhD founded “Biosearch” to supply research tools to the nascent Biotechnology industry. In the 1980s, Biosearch developed and manufactured automated, solid-phase DNA synthesizers, such as the SAM I, the Cyclone, Biosearch 8700 and Biosearch 8800 Prep. These instruments manufactured oligonucleotides with prodigious proficiency, catalyzing the development of revolutionary new oligo based technologies. Most notably in 1982, Kary Mullis then at Cetus Corporation, used a Biosearch Sam One DNA synthesizer to create oligos for use in his experiments, which eventually resulted in the discovery of the Polymerase Chain Reaction (PCR).
Kary Mullis and the Invention of PCR
Kary Mullis, who earned a PhD in biochemistry from University of California, Berkeley in 1973, conceived of PCR in the spring of 1983 as a means to amplify a specific locus of interest on the human genome.
After conceptualizing PCR during his famous drive to "Philo", Kary labored for a number of months to work out experimental conditions. Since thermostable polymerases were not yet available, it was necessary to add Klenow after each thermal cycle, adding to the tedium of development. There were many failures and many reasons why PCR should not work. After all the idea was so simple, shouldn’t it have been invented before? Ignoring the doubts of many, and with encouragement from Ron Cook as well as other supporters, Kary was able to perform his first successful experiment on December 16, 1983, and the rest, as they say, is history!!! A patent for PCR was awarded to Cetus Corporation, the company who employed Kary during the time of his discovery, and was later sold to Hoffmann-La Roche for $300 million.
The discovery of PCR forever changed the molecular biology world. It is a standard, yet indispensable research technique used for numerous medical and biological applications such as DNA sequencing and genetic fingerprinting. PCR was also the lone technique that helped the synthetic oligonucleotide business become a thriving industry. Hence 25 years later, Biosearch respectfully commemorates the development of a technique that swiftly answered past DNA chemistry problems with, as Kary describes, “Abundance and distinction.”
The Evolution of PCR
As PCR introduced capabilities to identify, manipulate, and amplify DNA, research possibilities flourished. The detection of genetic mutations, the ability to detect the presence of previously unknown genetic material, as well as the ability to analyze degraded DNA, all became common practice. For example, diseases such as muscular dystrophy and HIV were detected and diagnosed with the use of PCR.
As scientists grew more familiar with the technique of PCR, they began to expand on the utility of the method. During the late 1980s PCR was used to measure the quantity of DNA present in a reaction, generating the term “quantitative PCR” or more simply, q-PCR. This technique further improved PCR by the isolation of Taq Polymerase in the early nineties. The heat stable polymerase could remain active through many cycles of heat required for amplification and created the demand for faster cycling. Russell Higuchi and associates developed a system to monitor the amplification of DNA simultaneously to the reaction. The system involved ethidium bromide, a thermal cycler to irradiate samples with UV light, and a camera to record fluorescence.
In the early 90’s, fluorogenic dual labeled probes were developed as a means to practice q-PCR. In conjunction with fluorescent probes, PCR had further evolved into a sensitive quantification tool useful for the detection of any desired genetic element. As a result, the ability to measure gene expression and practice genotyping quickly became trivial and widespread throughout the biotechnology industry. Now, with the recent development of new dyes and quenchers such as the series of Black Hole Quencher®, CAL Fluor® and Quasar® dyes from Biosearch, the possibilities for PCR are seemingly endless.
